Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

333 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Trastuzumab (herceptin) for early-stage breast cancer.
Ismael G, Rosa DD, de Azambuja E, Braga S, Piccart-Gebhart M. Ismael G, et al. Among authors: de azambuja e. Hematol Oncol Clin North Am. 2007 Apr;21(2):239-56. doi: 10.1016/j.hoc.2007.03.003. Hematol Oncol Clin North Am. 2007. PMID: 17512447 Review.
Clinical practice-changing trials: the HERA study paradigm.
Zardavas D, Ades F, de Azambuja E. Zardavas D, et al. Among authors: de azambuja e. Expert Rev Anticancer Ther. 2013 Nov;13(11):1249-56. doi: 10.1586/14737140.2013.848168. Epub 2013 Oct 21. Expert Rev Anticancer Ther. 2013. PMID: 24138446 Review.
Cardiotoxicity of systemic agents used in breast cancer.
Ades F, Zardavas D, Pinto AC, Criscitiello C, Aftimos P, de Azambuja E. Ades F, et al. Among authors: de azambuja e. Breast. 2014 Aug;23(4):317-28. doi: 10.1016/j.breast.2014.04.002. Epub 2014 May 1. Breast. 2014. PMID: 24794210 Free article. Review.
Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors ≤ 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials.
O'Sullivan CC, Bradbury I, Campbell C, Spielmann M, Perez EA, Joensuu H, Costantino JP, Delaloge S, Rastogi P, Zardavas D, Ballman KV, Holmes E, de Azambuja E, Piccart-Gebhart M, Zujewski JA, Gelber RD. O'Sullivan CC, et al. Among authors: de azambuja e. J Clin Oncol. 2015 Aug 20;33(24):2600-8. doi: 10.1200/JCO.2015.60.8620. Epub 2015 Jun 22. J Clin Oncol. 2015. PMID: 26101239 Free PMC article.
Threat posed by unproven drugs in medical oncology.
Pondé N, Ades F, de Azambuja E. Pondé N, et al. Among authors: de azambuja e. ESMO Open. 2016 May 9;1(3):e000064. doi: 10.1136/esmoopen-2016-000064. eCollection 2016. ESMO Open. 2016. PMID: 27843615 Free PMC article. No abstract available.
333 results